Capricor Therapeutics (CAPR) Reports Q4 Loss of $0.21/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
March 15, 2017 4:10 PM EDTLOS ANGELES, March 15, 2017 /PRNewswire/ --Â Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today provided a corporate update and announced financial results for the fourth quarter and full year ended December 31, 2016.
"2016 was an eventful year for Capricor, marked by meaningful advances in our clinical development programs as well as notable corporate achievements," said Linda Marbán, Ph.D., president and chief executive officer.... More
